1. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Issue 9 (19th April 2014) Authors: Kavanaugh, Arthur; McInnes, Iain B; Mease, Philip; Krueger, Gerald G; Gladman, Dafna; van der Heijde, Désirée; Zhou, Yiying; Lu, Jiandong; Leu, Jocelyn H; Goldstein, Neil; Beutler, Anna Journal: Annals of the rheumatic diseases Issue: Volume 73:Issue 9(2014) Page Start: 1689 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Issue 3 (16th December 2013) Authors: Kay, Jonathan; Fleischmann, Roy; Keystone, Edward; Hsia, Elizabeth C; Hsu, Benjamin; Mack, Michael; Goldstein, Neil; Braun, Jürgen; Kavanaugh, Arthur Journal: Annals of the rheumatic diseases Issue: Volume 74:Issue 3(2015) Page Start: 538 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Issue 4 (April 2021) Authors: Pollard, Andrew J; Launay, Odile; Lelievre, Jean-Daniel; Lacabaratz, Christine; Grande, Sophie; Goldstein, Neil; Robinson, Cynthia; Gaddah, Auguste; Bockstal, Viki; Wiedemann, Aurelie; Leyssen, Maarten; Luhn, Kerstin; Richert, Laura; Bétard, Christine; Gibani, Malick M; Clutterbuck, Elizabeth A; ... Journal: Lancet infectious diseases Issue: Volume 21:Issue 4(2021) Page Start: 493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. (16th September 2020) Authors: Goldstein, Neil; Bockstal, Viki; Bart, Stephan; Luhn, Kerstin; Robinson, Cynthia; Gaddah, Auguste; Callendret, Benoit; Douoguih, Macaya Journal: Journal of infectious diseases Issue: Volume 226:Number 4(2022) Page Start: 595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Issue 1 (January 2022) Authors: Afolabi, Muhammed O; Ishola, David; Manno, Daniela; Keshinro, Babajide; Bockstal, Viki; Rogers, Baimba; Owusu-Kyei, Kwabena; Serry-Bangura, Alimamy; Swaray, Ibrahim; Lowe, Brett; Kowuor, Dickens; Baiden, Frank; Mooney, Thomas; Smout, Elizabeth; Köhn, Brian; Otieno, Godfrey T; Jusu, Morrison; Fost... Journal: Lancet infectious diseases Issue: Volume 22:Issue 1(2022) Page Start: 110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Issue 1 (January 2022) Authors: Ishola, David; Manno, Daniela; Afolabi, Muhammed O; Keshinro, Babajide; Bockstal, Viki; Rogers, Baimba; Owusu-Kyei, Kwabena; Serry-Bangura, Alimamy; Swaray, Ibrahim; Lowe, Brett; Kowuor, Dickens; Baiden, Frank; Mooney, Thomas; Smout, Elizabeth; Köhn, Brian; Otieno, Godfrey T; Jusu, Morrison; Fost... Journal: Lancet infectious diseases Issue: Volume 22:Issue 1(2022) Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗